Sermorelin, hexarelin, and 'Manjaro' peptide stacking claims reviewed

What did @drstayyoung actually say?

The creator pitched sermorelin plus hexarelin as "the best peptide stack that anyone can use," arguing that the two work together to amplify growth hormone and burn stubborn fat. They also threw in a reference to "Manjaro" (presumably tirzepatide, sold as Mounjaro) as something you can skip if you just use peptides instead. The stack is described as injected subcutaneously daily, with "holidays" built in. The pitch ends with a promise of faster recovery, better skin, improved sleep, and hormonal optimization.

This is a lot of ground to cover in a short video, and some of it is grounded in real pharmacology. But some of it veers into oversimplification and at least one claim is a straight substitution myth that deserves a hard look.

Does the science back this up?

Partially, yes. But the gaps matter. Sermorelin is a GHRH analogue with a reasonable evidence base for stimulating pituitary GH release. Hexarelin is a synthetic GHSR agonist with documented GH-releasing and some cardiovascular effects in research settings. The synergy angle is real in principle.

Sermorelin's effects on GH secretion are well-documented in older adults. Walker et al. (1994, Journal of Clinical Endocrinology and Metabolism) showed pulsatile GH restoration in GH-deficient adults. Hexarelin's receptor activity on ghrelin receptors (GHSR-1a) is also established in preclinical work, including Ghigo et al. (1994, Journal of Clinical Endocrinology and Metabolism). However, most human trials on hexarelin specifically are small, short-term, or decades old. The fat-burning claim for hexarelin specifically is not well-supported by robust human RCT data. That's a meaningful distinction the video skips entirely.

What did they get wrong (or right)?

They got the basic mechanism right. Sermorelin does act on the hypothalamus to stimulate GHRH signaling. Hexarelin does bind ghrelin receptors. Growth hormone does decline with age, and that decline can begin in the third decade of life, not just after 40 as implied. Bowers et al. (2004, Growth Hormone and IGF Research) confirmed GH pulse amplitude decreases progressively from young adulthood.

Where it breaks down: the claim that hexarelin burns "those extra five to six stubborn pounds" and that this is a substitute for tirzepatide is not supported. Tirzepatide works on GIP and GLP-1 receptors with a completely different mechanism and has phase 3 RCT data behind it (Jastreboff et al., 2022, NEJM). Hexarelin has no comparable human weight-loss trial data. Framing these as interchangeable options is misleading and potentially steers people away from clinically validated treatments.

Also worth flagging: the creator misspells or mispronounces both sermorelin ("Samoralin") and tirzepatide ("Manjaro" in the caption, "terzepitide" in the transcript). These are not the same drug, and sloppy naming on a health platform with 12K views is a real problem.

What should you actually know?

Peptide stacking is a real clinical concept, but "the best stack that anyone can use" does not exist. Individual response to GH-stimulating peptides varies based on baseline GH status, age, sex, and existing health conditions. Someone with normal GH levels pushing them higher is not the same as someone with documented deficiency restoring physiologic levels.

Both sermorelin and hexarelin require a prescription and should be prescribed and monitored by a licensed provider. Hexarelin in particular has shown transient cortisol and prolactin elevations in human studies (Arvat et al., 1997, Journal of Clinical Endocrinology and Metabolism), which is relevant for anyone with adrenal or pituitary concerns. These are not wellness supplements you self-stack based on a TikTok video.

The "skip Ozempic and Mounjaro" framing is the most dangerous moment in this video. If someone has metabolic disease, insulin resistance, or obesity-related health risk, directing them toward an unproven peptide stack instead of an evidence-based GLP-1 therapy could cause real harm. A regulated telehealth provider should never make that substitution call in a 60-second video.

FormBlends bottom line

Some of the pharmacology here is directionally correct. The synergy rationale between a GHRH analogue and a GHSR agonist has biological logic behind it. But the fat-loss claims for hexarelin are overstated, the "Manjaro" comparison is irresponsible, and presenting this stack as universally applicable ignores the individual assessment any legitimate prescriber would require. If you're curious about peptide therapy, start with a provider who orders labs, not one who promises results in a caption.